Want to take quizzes and track your credits?
COVID-19, which is due to infection with SARS-CoV-2, results in poor outcomes in patients with hematologic cancers (approximately 40% mortality rate).1,2 The efficacy of anti-SARS-CoV-2 mRNA vaccines has been successfully demonstrated in healthy populations3 and also has been reported in immunocompromised patients. Recently, we showed that a first injection of the BNT162b2 (Pfizer-BioNTech) vaccine induced an antibody response in 55% of 112 allogeneic hematopoietic stem cell transplant (HSCT) recipients.4 Here, we document the antibody response to a second dose of BNT162b2 vaccine in an extended cohort of 117 patients.
Sign in to take quiz and track your certificates
Accepted for Publication: July 19, 2021.
Published: September 14, 2021. doi:10.1001/jamanetworkopen.2021.26344
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Le Bourgeois A et al. JAMA Network Open.
Corresponding Author: Patrice Chevallier, MD, PhD, Hematology Department, Nantes University Hospital, Centre Hospitalo-Universitaire Hotel-Dieu, Place A Ricordeau, 44093 Nantes Cedex, France (email@example.com).
Author Contributions: Drs Le Bourgeois and Chevallier had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Le Bourgeois, Guillaume, Chevallier.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Guillaume, Chevallier.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Béné, Chevallier.
Administrative, technical, or material support: Coste-Burel, Guillaume, Garnier, Chevallier.
Supervision: Le Bourgeois, Béné.
Conflict of Interest Disclosures: Dr Chevallier reported receiving honoraria from Pfizer outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank the paramedical staff of the Hematology Department and of the Virology Department, Nantes University Hospital, for their assistance. Berthe-Marie Imbert, PharmD, PhD, Thomas Drumel, PharmD, Beatrice Mahé, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Anne Lok, MD, Cyrille Touzeau, MD, PhD, Thomas Gastinne, MD, Maxime Jullien, MD, Sophie Vanthygem, MD, Philippe Moreau, MD, and Steven Le Gouill, MD, PhD (all from Nantes University Hospital), provided data and commented on the manuscript. Patricia Lespart, Nursing Diploma, Ghislaine Francois, Nursing Diploma, and Katia Godart, Nursing Diploma (all from the Hematology Department, Nantes University Hospital) administered vaccines and helped collect samples and questionnaires. None of these individuals was compensated beyond their normal salaries.
You currently have no searches saved.